Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16334318 | 0.93 | CYSLTR2 (0.50) | LTA4HCYSLTR2CYSLTR1BRD4MAPT | |
| SCHEMBL17288159 | 0.85 | GAA (0.55) | TSHRMAPTPOLBKDM4EHSD17B10 | |
| SCHEMBL21991849 | 0.81 | MAPT (0.58) | LTA4HL3MBTL1TSHRMAPTPOLB | |
| SCHEMBL3951838 | 0.78 | L3MBTL1 (0.66) | LTA4HL3MBTL1TSHRPOLBKDM4E | |
| SCHEMBL4590909 | 0.78 | CYP4F2 (0.58) | MAPTTDP1 | |
| SCHEMBL25385132 | 0.77 | BRD4 (0.51) | LTA4HL3MBTL1BRD4TSHRMAPT | |
| SCHEMBL7692040 | 0.76 | LTA4H (0.52) | LTA4HL3MBTL1CYSLTR2CYSLTR1TSHR | |
| SCHEMBL21992555 | 0.76 | MAPT (0.60) | LTA4HMAPTPOLB | |
| SCHEMBL7692039 | 0.76 | LTA4H (0.52) | LTA4HL3MBTL1CYSLTR2CYSLTR1BRD4 | |
| SCHEMBL256095 | 0.76 | CHRNB2 (0.45) | LTA4HMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708299-B2 | Hedgehog antagonists having zinc binding moieties | GENENTECH, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GENETECH, INC. (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GLI1, SHH, HDAC1 | LTA4H 3049/4885L3MBTL1 1382/4885CYSLTR2 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.